Skip to main content
Top
Published in: Clinical Rheumatology 5/2005

01-10-2005 | Original Article

Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti-topoisomerase I (Scl-70) antibodies

Authors: D. Villalta, N. Bizzaro, S. Platzgummer, A. Antico, M. Tampoia, L. Camogliano, D. Bassetti, M. Pradella, A. Piazza, F. Manoni, R. Tozzoli, E. Tonutti

Published in: Clinical Rheumatology | Issue 5/2005

Login to get access

Abstract

Reports of a possible correlation between anti-Scl-70 antibody concentration and clinical manifestations in systemic sclerosis patients have recently appeared in the scientific literature. The goal of our study was to evaluate, by means of a multicenter study, the analytical reliability of immunoassay systems in the quantitative measurement of Scl-70 antibodies. Three blind samples (H, M, L) at different anti-Scl-70 antibody concentrations, and a low concentration antibody serum (LPC) used as a common calibrator, were sent three times in a 6-month time span to 39 Italian clinical laboratories. Each laboratory was asked to calculate dosages following the enzyme-linked immunosorbent assay (ELISA) method they used and report the optical density values of each sample (ODs), of the cutoff serum provided by the manufacturer of the kit used (ODco) and of LPC (ODLPC). The overall analytical imprecision (between methods and between laboratories) of the three different determinations of the values respectively expressed in ODs, ODs/ODco and ODs/ODLPCratio was 47.1, 52.8 and 34.0% for sample H, 56.2, 47.4% and 34% for sample M and 84.6, 86.0 and 86.6% for sample L. The average intra-method analytical imprecision was, respectively, 20.7, 29.8 and 18.6% for sample H, 24.6, 26.5 and 19.3% for sample M, and 30.6, 28.1 and 20.2% for sample L. The commercial ELISA methods currently used to determine the presence of anti-Scl-70 autoantibodies show considerable differences in the quantitative determination. The best results for reproducibility analyses have been obtained when the values were expressed as a ratio between the ODs of the sample and of the common calibrator (ODs/ODLPC). Forward-looking clinical studies that can clarify the usefulness of quantitative determination of anti-Scl-70 antibodies in the monitoring of diffuse scleroderma patients can be performed only when standard serum with a known antibody concentration and calibration curves for quantitative ELISA measurements are made available.
Literature
1.
go back to reference Tan EM (1987) Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 33:167–240 Tan EM (1987) Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 33:167–240
2.
go back to reference Rothfield NF, Stollar BD (1967) The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 46:1785–1792PubMed Rothfield NF, Stollar BD (1967) The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 46:1785–1792PubMed
3.
go back to reference Isenberg DA, Shoenfeld Y, Schwartz RS (1984) Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum 27:132–138PubMed Isenberg DA, Shoenfeld Y, Schwartz RS (1984) Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum 27:132–138PubMed
4.
go back to reference Tan EM, Kunkel HG (1968) Characteristics of a soluble nuclear antigen precipitating with sera of patients with lupus erythematosus. J Immunol 96:464–471 Tan EM, Kunkel HG (1968) Characteristics of a soluble nuclear antigen precipitating with sera of patients with lupus erythematosus. J Immunol 96:464–471
5.
go back to reference Fritzler MJ, Kinsella TD, Garbutt E (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526PubMed Fritzler MJ, Kinsella TD, Garbutt E (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526PubMed
6.
go back to reference Shero J, Bordwell B, Rothfield NF, Earnshaw WC (1986) High titer of antibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 231:737–740PubMed Shero J, Bordwell B, Rothfield NF, Earnshaw WC (1986) High titer of antibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 231:737–740PubMed
7.
go back to reference Schur PH, Sandson J (1968) Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 278:533–538PubMed Schur PH, Sandson J (1968) Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 278:533–538PubMed
8.
go back to reference Reichlin M, Brucato A, Frank MB, Maddison PJ, McCubbin VR, Wolfson-Reichlin M et al (1994) Concentration of autoantibodies to native 60-kd Ro/SSA and 52-kd Ro/SSA in eluates from the heart of a child who died with congenital complete heart block. Arthritis Rheum 37:1698–1703PubMed Reichlin M, Brucato A, Frank MB, Maddison PJ, McCubbin VR, Wolfson-Reichlin M et al (1994) Concentration of autoantibodies to native 60-kd Ro/SSA and 52-kd Ro/SSA in eluates from the heart of a child who died with congenital complete heart block. Arthritis Rheum 37:1698–1703PubMed
9.
go back to reference Jacobsen S, Halberg P, Ullman S, Høler-Madsen M, Petersen J, Mortensen J et al (1997) A longitudinal study of pulmonary functions in Danish patients with systemic sclerosis. Clin Rheumatol 16:384–390PubMed Jacobsen S, Halberg P, Ullman S, Høler-Madsen M, Petersen J, Mortensen J et al (1997) A longitudinal study of pulmonary functions in Danish patients with systemic sclerosis. Clin Rheumatol 16:384–390PubMed
10.
go back to reference Diot E, Giraudeau B, Diot B, Degenne D, Ritz L, Guilmot JL et al (1999) Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 116:715–720PubMed Diot E, Giraudeau B, Diot B, Degenne D, Ritz L, Guilmot JL et al (1999) Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 116:715–720PubMed
11.
go back to reference Koffler D, Agnello V, Thoburn R, Kunkel HG (1971) Systemic lupus erythematosus prototype of immune complex nephritis in man. J Exp Med 134 [Suppl]:169 Koffler D, Agnello V, Thoburn R, Kunkel HG (1971) Systemic lupus erythematosus prototype of immune complex nephritis in man. J Exp Med 134 [Suppl]:169
12.
go back to reference Morioka T (1996) Anti-DNA antibody derived from a systemic lupus erythematosus (SLE) patients forms histone-DNA-antiDNA complexes that bind to rat glomeruli in vivo. Clin Exp Immunol 104:92–100PubMed Morioka T (1996) Anti-DNA antibody derived from a systemic lupus erythematosus (SLE) patients forms histone-DNA-antiDNA complexes that bind to rat glomeruli in vivo. Clin Exp Immunol 104:92–100PubMed
13.
go back to reference Tan EM, Schur PH, Carr RI, Kunkel HG (1966) Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 45:1732–1740PubMed Tan EM, Schur PH, Carr RI, Kunkel HG (1966) Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 45:1732–1740PubMed
14.
go back to reference Swaak AJG, Aarden LA, Statius van Epps LW, Feltkamp TEW (1978) Anti-dsDNA and complement profiles as prognostic guide in systemic lupus erythematosus. Arthritis Rheum 22:226–235 Swaak AJG, Aarden LA, Statius van Epps LW, Feltkamp TEW (1978) Anti-dsDNA and complement profiles as prognostic guide in systemic lupus erythematosus. Arthritis Rheum 22:226–235
15.
go back to reference Smeenk RJT, Berden JHM, Swaak AJG (1996) dsDNA autoantibodies. In: Peter JB, Shoenfeld Y (eds) Autoantibodies. Elsevier Science BV, Amsterdam, pp 227–236 Smeenk RJT, Berden JHM, Swaak AJG (1996) dsDNA autoantibodies. In: Peter JB, Shoenfeld Y (eds) Autoantibodies. Elsevier Science BV, Amsterdam, pp 227–236
16.
go back to reference Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF et al (1989) Association between active Wegener’s granulomatosis and anti-cytoplasmatic antibodies. Arch Intern Med 149:2461–2465PubMed Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF et al (1989) Association between active Wegener’s granulomatosis and anti-cytoplasmatic antibodies. Arch Intern Med 149:2461–2465PubMed
17.
go back to reference Tervaert JW, Huitema MG, Henè RJ, Sluiter WJ, The TH, van der Hem GK et al (1990) Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 336:709–711PubMed Tervaert JW, Huitema MG, Henè RJ, Sluiter WJ, The TH, van der Hem GK et al (1990) Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 336:709–711PubMed
18.
go back to reference Houtman PM, Kallenberg CGM, Limburg PC, Huitema MG, van Rijswijk MH, The TH (1985) Quantitation of autoantibodies to nucleoribonucleoprotein by ELISA: relation between antibody levels and disease activity in patients with connective tissue disease. Clin Exp Immunol 62:696–704PubMed Houtman PM, Kallenberg CGM, Limburg PC, Huitema MG, van Rijswijk MH, The TH (1985) Quantitation of autoantibodies to nucleoribonucleoprotein by ELISA: relation between antibody levels and disease activity in patients with connective tissue disease. Clin Exp Immunol 62:696–704PubMed
19.
go back to reference Habets WJA, Hoet MH, Sillrkens PTG, De Rooij DJRAM, van De Putte LBA, van Venrooij WJ (1989) Detection of autoantibodies in a quantitative immunoassay using recombinant ribonucleoprotein antigens. Clin Exp Immunol 76:172–177PubMed Habets WJA, Hoet MH, Sillrkens PTG, De Rooij DJRAM, van De Putte LBA, van Venrooij WJ (1989) Detection of autoantibodies in a quantitative immunoassay using recombinant ribonucleoprotein antigens. Clin Exp Immunol 76:172–177PubMed
20.
go back to reference Nyman U, Lundberg I, Hedfors E, Wahren M, Petterson I (1972) IgG and IgM anti-snRNP reaction in sequentially obtained serum samples from patients with connective tissue diseases. Ann Rheum Dis 51:1307–1312 Nyman U, Lundberg I, Hedfors E, Wahren M, Petterson I (1972) IgG and IgM anti-snRNP reaction in sequentially obtained serum samples from patients with connective tissue diseases. Ann Rheum Dis 51:1307–1312
21.
go back to reference De Rooij DJRAM, Habets WJ, van de Putte JBA, Hoet MH, Verbek AL, van Venrooij WJ (1990) Use of recombinant RNP peptides to 70 K and A in an ELISA for measurement of antibodies in mixed connective tissue disease: a longitudinal follow up of 18 patients. Ann Rheum Dis 49:391–395PubMed De Rooij DJRAM, Habets WJ, van de Putte JBA, Hoet MH, Verbek AL, van Venrooij WJ (1990) Use of recombinant RNP peptides to 70 K and A in an ELISA for measurement of antibodies in mixed connective tissue disease: a longitudinal follow up of 18 patients. Ann Rheum Dis 49:391–395PubMed
22.
go back to reference Hoet RM, Koornneef I, De Rooij DJ, van de Putte LB, van Venrooij WJ (1992) Changes in anti-U1RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome. Arthritis Rheum 35:1202–1210PubMed Hoet RM, Koornneef I, De Rooij DJ, van de Putte LB, van Venrooij WJ (1992) Changes in anti-U1RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome. Arthritis Rheum 35:1202–1210PubMed
23.
go back to reference Yamamoto AM, Amoura Z, Johannet C, Jeronimo ALC, Campos H, Koutouzov S et al (2000) Quantitative radioligand assays using de novo-synthesized recombinant autoantigens in connective tissue diseases. Arthritis Rheum 43:689–698PubMed Yamamoto AM, Amoura Z, Johannet C, Jeronimo ALC, Campos H, Koutouzov S et al (2000) Quantitative radioligand assays using de novo-synthesized recombinant autoantigens in connective tissue diseases. Arthritis Rheum 43:689–698PubMed
24.
go back to reference Wahren M, Tengner P, Gunnarsson I, Lundberg I, Hedfors E, Ringertz NR et al (1998) Ro/SSA and La/SSB antibody level variation in patients with Sjögren’s syndrome and systemic lupus erythematosus. J Autoimmun 11:29–38PubMed Wahren M, Tengner P, Gunnarsson I, Lundberg I, Hedfors E, Ringertz NR et al (1998) Ro/SSA and La/SSB antibody level variation in patients with Sjögren’s syndrome and systemic lupus erythematosus. J Autoimmun 11:29–38PubMed
25.
go back to reference Hassan AB, Lundberg IE, Isenberg D, Wahren-Herlenius M (2002) Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scand J Rheumatol 31:133–139PubMed Hassan AB, Lundberg IE, Isenberg D, Wahren-Herlenius M (2002) Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scand J Rheumatol 31:133–139PubMed
26.
go back to reference Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T (2000) Longitudinal analysis of antibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 43:1074–1084PubMed Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T (2000) Longitudinal analysis of antibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 43:1074–1084PubMed
27.
go back to reference Hildebrant S, Jackh G, Weber S, Peter HH (1993) A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies. Rheumatol Int 12:231–234PubMed Hildebrant S, Jackh G, Weber S, Peter HH (1993) A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies. Rheumatol Int 12:231–234PubMed
28.
go back to reference Sato S, Hamaguchi Y, Hasegawa M, Takehara K (2001) Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology 40:1135–1140PubMed Sato S, Hamaguchi Y, Hasegawa M, Takehara K (2001) Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology 40:1135–1140PubMed
29.
go back to reference Gussin HAE, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44:376–383PubMed Gussin HAE, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44:376–383PubMed
30.
go back to reference Brada FA, Andrews BS, Davis JS, Taylor RN (1981) Antibodies to Sm in patients with systemic lupus erythematosus. Arthritis Rheum 24:1236–1244PubMed Brada FA, Andrews BS, Davis JS, Taylor RN (1981) Antibodies to Sm in patients with systemic lupus erythematosus. Arthritis Rheum 24:1236–1244PubMed
31.
go back to reference Habets WJ, De Rooij DJ, Hoet MH, van de Putte LB, van Venrooij WJ (1985) Quantitation of anti-RNP and anti-Sm antibodies in MCTD and SLE patients by immunoblotting. Clin Exp Immunol 59:457–466PubMed Habets WJ, De Rooij DJ, Hoet MH, van de Putte LB, van Venrooij WJ (1985) Quantitation of anti-RNP and anti-Sm antibodies in MCTD and SLE patients by immunoblotting. Clin Exp Immunol 59:457–466PubMed
32.
go back to reference Tozzoli R, Bizzaro N, Tonutti E, Pradella M, Manoni F, Villalta D et al (2002) Immunoassay of anti-thyroid autoantibodies: high analytical variability in second generation methods. Clin Chem Lab Med 40:568–572PubMed Tozzoli R, Bizzaro N, Tonutti E, Pradella M, Manoni F, Villalta D et al (2002) Immunoassay of anti-thyroid autoantibodies: high analytical variability in second generation methods. Clin Chem Lab Med 40:568–572PubMed
33.
go back to reference Bizzaro N, Tonutti E, Villalta D, Bassetti D, Tozzoli R, Manoni F et al (2000) Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl70) autoantibodies: results of a multicenter study. Clin Chem 46:1681–1685PubMed Bizzaro N, Tonutti E, Villalta D, Bassetti D, Tozzoli R, Manoni F et al (2000) Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl70) autoantibodies: results of a multicenter study. Clin Chem 46:1681–1685PubMed
34.
go back to reference Hu PQ, Fertig N, Medsger TA, Wright TM (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48:1363–1373PubMed Hu PQ, Fertig N, Medsger TA, Wright TM (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48:1363–1373PubMed
35.
go back to reference Steen VD, Powell DL, Medsger TA (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196–203PubMed Steen VD, Powell DL, Medsger TA (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196–203PubMed
36.
go back to reference Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M (1986) Different antibody patterns and different prognoses in patients with sclerodermia with various extent of skin sclerosis. J Rheumatol 13:911–916PubMed Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M (1986) Different antibody patterns and different prognoses in patients with sclerodermia with various extent of skin sclerosis. J Rheumatol 13:911–916PubMed
37.
go back to reference Aeschlimann A, Meyer O, Bourgeois P, Haim T, Belmatourg N, Palazzo E et al (1989) Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations. Ann Rheum Dis 48:992–997PubMed Aeschlimann A, Meyer O, Bourgeois P, Haim T, Belmatourg N, Palazzo E et al (1989) Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations. Ann Rheum Dis 48:992–997PubMed
38.
go back to reference Briggs DC, Vaughan RW, Welsh KI, Myers A, duBois RM, Black CM (1991) Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis patients. Lancet 338:661–662PubMed Briggs DC, Vaughan RW, Welsh KI, Myers A, duBois RM, Black CM (1991) Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis patients. Lancet 338:661–662PubMed
39.
go back to reference Reveille JD, Solomon DH, The American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Care Res 49:399–412 Reveille JD, Solomon DH, The American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Care Res 49:399–412
40.
go back to reference Vazquez-Abad D, Russel CA, Cusick SM, Earnshaw WC, Rothfield NF (1995) Longitudinal study of anticentromere and antitopoisomerase-I isotypes. Clin Immunol Immunopathol 74:257–270PubMed Vazquez-Abad D, Russel CA, Cusick SM, Earnshaw WC, Rothfield NF (1995) Longitudinal study of anticentromere and antitopoisomerase-I isotypes. Clin Immunol Immunopathol 74:257–270PubMed
41.
go back to reference Tan EM, Smolen JS, Mc Dougal JS, Butcher BT, Conn D, Dawkins R et al (1999) A critical evaluation of enzyme immunoassay for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity and specificity. Arthritis Rheum 42:455–464PubMed Tan EM, Smolen JS, Mc Dougal JS, Butcher BT, Conn D, Dawkins R et al (1999) A critical evaluation of enzyme immunoassay for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity and specificity. Arthritis Rheum 42:455–464PubMed
42.
go back to reference Tan EM, Smolen JS, Mc Dougal JS, Fritzler MJ, Gordon T, Hardin JA et al (2002) A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol 29:68–74PubMed Tan EM, Smolen JS, Mc Dougal JS, Fritzler MJ, Gordon T, Hardin JA et al (2002) A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol 29:68–74PubMed
Metadata
Title
Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti-topoisomerase I (Scl-70) antibodies
Authors
D. Villalta
N. Bizzaro
S. Platzgummer
A. Antico
M. Tampoia
L. Camogliano
D. Bassetti
M. Pradella
A. Piazza
F. Manoni
R. Tozzoli
E. Tonutti
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2005
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-1054-9

Other articles of this Issue 5/2005

Clinical Rheumatology 5/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.